Dyax DX-88 Submission Likely Postponed For Additional Dosing Study
FDA seeks a subcutaneous dose-ranging study on the recombinant protein to treat hereditary angioedema.
FDA seeks a subcutaneous dose-ranging study on the recombinant protein to treat hereditary angioedema.